BGHDX — Baillie Gifford Health Innovation Equities Fund
Data updated: 2025-03-10
BGHDX — Baillie Gifford Health Innovation Equities Fund data: holdings, portfolio allocation, expenses, performance, cashflows, risk and SEC filings. Global (incl. US) Thematic Equity · $6.30M AUM · 0.65% expense ratio · -3.7% 1-yr return. From SEC regulatory filings.
BGHDX Fund Overview
BGHDX — Baillie Gifford Health Innovation Equities Fund is a US mutual fund managed by Baillie Gifford Funds, categorised as Global (incl. US) Thematic Equity. ABC INVEST provides holdings, performance, costs, cashflows, risk data, prospectus documents and SEC filings, sourced from SEC filings.
- Type: US mutual fund
- Manager: Baillie Gifford Funds
- Category: Global (incl. US) Thematic Equity
- Assets under management: $6.30M
- 1-year return: -3.7%
- Ticker: BGHDX
- SEC CIK: 0001120543
- SEC series ID: S000074799
- Share class ID: C000233009
BGHDX Holdings
Top 10 holdings of Baillie Gifford Health Innovation Equities Fund by percentage of net assets, from the fund's latest SEC N-PORT filing.
| Holding | % of net assets |
|---|---|
| Argenx SE | 7.58% |
| Alnylam Pharmaceuticals Inc | 7.11% |
| ALK-Abello A/S | 5.61% |
| Ambu A/S | 5.10% |
| Genmab A/S | 4.41% |
| Insulet Corp | 4.26% |
| Exact Sciences Corp | 4.07% |
| ResMed Inc | 3.89% |
| Moderna Inc | 3.72% |
| Doximity Inc | 3.61% |
BGHDX Portfolio Allocation
Asset-class allocation of Baillie Gifford Health Innovation Equities Fund by percentage of net assets, from the latest SEC N-PORT filing.
| Asset class | Allocation |
|---|---|
| Equity | 99.0% |
BGHDX Performance
Total returns for BGHDX (as of 2026-08-01), from SEC filings.
| Period | Total return |
|---|---|
| 1 year | -3.7% |
| 3 years (annualised) | -16.9% |
BGHDX Risk Information
Risk metrics for BGHDX, derived from monthly returns in SEC filings.
- 1-year volatility (annualised): 10.7%
BGHDX Costs and Fees
BGHDX costs about $65 per $10,000 invested per year in fund expenses.
- Net expense ratio: 0.65%
- Gross expense ratio: 1.56%
- Portfolio turnover: 23%
- Brokerage commissions: 4.22 bps of average net assets (SEC N-CEN)
BGHDX Cashflows
Over the 12 months to 2024-12, Baillie Gifford Health Innovation Equities Fund had net outflows of $8.98M, from monthly SEC N-PORT filings.
| Month | Net flow |
|---|---|
| 2024-12 | −$28.39K |
| 2024-11 | −$204.72K |
| 2024-10 | $1.50K |
| 2024-09 | −$29.62K |
| 2024-08 | −$96.39K |
| 2024-07 | −$9.49M |
BGHDX Debt Constituents
No individual debt constituents are reported in Baillie Gifford Health Innovation Equities Fund's latest SEC N-PORT filing.
BGHDX Prospectus and SEC Filings
Official Baillie Gifford Health Innovation Equities Fund filings on SEC EDGAR — prospectus, portfolio holdings and annual reports.
Related Funds
Other Global (incl. US) Thematic Equity funds tracked on ABC INVEST:
Data Sources
ABC INVEST compiles this page from public filings made to the U.S. Securities and Exchange Commission (SEC) through EDGAR: portfolio holdings and monthly cashflows from Form N-PORT, expenses and returns from fund prospectuses (Form 485BPOS) and the SEC DERA Risk/Return Summary data sets, annual data from Form N-CEN, and shareholder reports from Form N-CSR.